MYSummit Conference 2021
October 7-9, 2021, Edinburgh, UK
Radisson Blu Hotel
Faith Davies, MD
Faith Davies, MD
Director, Clinical Myeloma Program
Department of Medicine
NYU Langone Medical Center
New York, USA
Faith Davies, MBBCh, MRCP, MD, FRCPath, is Member of the Faculty, Department of Medicine and Director of the Clinical Myeloma Program at NYU Langone Medical Center, in New York, NY, USA.
Dr. Davies is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Dr. Davies earned her medical degree from the College of Medicine, University of Wales. She completed general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.
Dr. Davies’s focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting.
Dr. Davies is a member of the British Society of Hematology, the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians, UK, and the Royal College of Pathologists, UK.
Graham Jackson, MD, PhD
Graham Jackson, MD, PhD
Professor of Hematology
Northern Institute for Cancer Research Newcastle University
Professor Jackson works in Hematology/Oncology and Bone Marrow Transplantation at Newcastle Hospitals NHS Foundation Trust and is a Professor of Clinical Haematology at Newcastle University. He graduated from Cambridge in 1980 and went on to study medicine at the Westminster School of Medicine. He gained his MRCP in 1986 and then moved to Newcastle University to undertake his MD, which he completed in 1992. Professor Jackson obtained his MRCPath in 1993, followed by his FRCP in 1999 and his FRCPath in 2000. He also worked at the Fred Hutchinson Cancer Centre in Seattle.
His research interests focus on the role of drug resistance in myeloma, development of long-term bone marrow transplant follow-up clinics, and the cytokine profile of acute and chronic GVHD. Clinically he has been involved in writing a number of guidelines including the BCSH anti-fungal guidelines. Professor Jackson has written a number of book chapters and has published more than 125 peer reviewed papers.
He was the President of the British Society of Haematology in 2014 and was the treasurer of the society until April 2013. He is also the President of the British Society of Blood and Marrow Transplantation (BSBMT) and serves on the Clinical Trials Awards and Advisory Committee (CTAAC) as well as the Leukaemia and Lymphoma Research grants committee. He is also actively involved in the national myeloma trials committee.
Xavier Leleu, MD, PhD
Xavier Leleu, Md, PhD
Professor, Head of the Myeloma Clinic
Head of the Department of Haematology
Hôpital de la Milétrie
Xavier Leleu, MD, PhD, is Professor, Head of the myeloma clinic and head of the department of Haematology at Hôpital La Mileterie, part of the academic hospital of Poitiers (CHU), France.
Dr Leleu received his medical degree at the University of Bordeaux, France. He completed specialization in public healthcare and statistics at the University of Medicine of Paris, France and in haematology at the University of Medicine of Lille. Dr Leleu was the head of the Myeloma clinic in Lille under Pr T Facon mentorship for almost 15 years. He received a Master’s in cellular biology at the University of Medicine of Lille in 2001 and completed his PhD in 2007 having done his research at Dana-Farber Cancer Institute, affiliated with Harvard Medical School, Boston, MA, USA. His main topic of research was the preclinical development of the novel agent and understanding mechanisms of resistance and of dormancy in Waldenström macroglobulinaemia and the clinical development of novel agents in multiple myeloma in the context of the most recent discovery in the biology of myeloma. He was trained with his mentors, Dr IM Ghobrial and Dr SP Treon, in Prof. Kenneth Anderson’s laboratory.
Doctor Leleu’s research is focussed on the biology and treatment of multiple myeloma, Waldenström’s macroglobulinemia and amyloidosis and he has published widely in the area. He is actively involved in numerous national and international clinical trials as investigator and coordinator. Professor Leleu is a frequent speaker at national and international congresses and is a reviewer or a member of the editorial board of several haematology journals. He is actively involved in the Intergroupe Francophone du Myélome (IFM), currently the treasurer and a member of the board of director and is also a member of a number of other national and international scientific societies.
Chief Executive, Myeloma Patients Europe
Myeloma Patients Europe AISBL
Avenue Louise 149/24
Ananda Plate is Chief Executive Officer at Myeloma Patients Europe (MPE). She joined the team in March 2013.
Ananda holds a law degree from the University of Barcelona and a master’s degree in Health Policy, Planning and Financing from the London School of Economics and Political Science and the London School of Hygiene and Tropical Medicine. Her main field of interest is cross border healthcare within the EU and health data protection.
Ananda started getting involved in patient advocacy in 2007. Since then she has collaborated with a number of patient organisations across Europe. She has worked at the leading Institute of Public Law (IDP Barcelona) and the European Commission (DG Health and Consumers). Currently Ananda is also Vice-chair of the Workgroup of European Cancer Patient Advocacy Networks (WECAN) and a member of the Ethics Committee at the Chamber of Physicians of Bavaria, Germany.
Ananda speaks Spanish, German, English, Catalan and French. She is currently based in Munich, Germany.